Article

Pragmatic Strategy for Fecal Specimen Storage and the Corresponding Test Methods for Clostridioides difficile Diagnosis

Seong Won Nho 1,†, Minjae Kim 1,‡, Seong-Jae Kim 1,‡, Steven L. Foley 1, Rajesh Nayak 2, Ohgew Kweon 1,* and Carl E. Cerniglia 1,*

1 Division of Microbiology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR 72079, USA; seongwon.nho@fda.hhs.gov (S.W.N.); minjaekim45@gmail.com (M.K.); seongjae.kim@fda.hhs.gov (S.-J.K.); steven.foley@fda.hhs.gov (S.L.F.)
2 Office of Regulatory Compliance and Risk Management, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR 72079, USA; Rajesh.nayak@fda.hhs.gov
* Correspondence: oh-gew.kweon@fda.hhs.gov (O.K.); carl.cerniglia@fda.hhs.gov (C.E.C.)
† These authors contributed equally to this work.
‡ Present address: Natural Resource Ecology Laboratory, Colorado State University, Fort Collins, CO 80523, USA.

Abstract: The quality of fecal specimens is one of the factors responsible for successful Clostridioides difficile infection (CDI) diagnosis. The quality depends largely on the storage conditions, including the temperature and time period. In this study, we organized the outputs of previous studies, filled experimental gaps in the knowledge of storage conditions, and introduced a pragmatic strategy for fecal storage for CDI diagnosis. A 5-step pathway was adopted to develop the fecal specimen storage strategy as follows: step 1, bibliometric analysis; step 2, experimental gap-filling; step 3, comparative evaluation; step 4, strategy development; step 5, internal review. Step 1 identified eight articles providing experimental information on the effects of fecal specimen storage conditions on the effectiveness of C. difficile detection methods. Step 2 provided additional quantitative data on C. difficile vegetative and spore cell viability and DNA stability. All previous and current results were compared (step 3). In step 4, 14 general and nine special strategies were developed, followed by an internal review of the overall approaches (step 5). It is recommended to separate fecal samples into aliquots before testing and storing them. It is particularly recommended that fecal specimen samples be stored for CDI diagnosis at 4 °C for up to 60 days for all test methods.

Keywords: Clostridioides difficile; CDI diagnosis; fecal specimen; real-time PCR; storage condition; bibliometric data

1. Introduction

A Gram-positive, spore-forming, and obligate anaerobic bacterium, Clostridioides difficile, is responsible for the majority of recently increasing cases of infectious antibiotic-associated diarrhea and pseudomembranous colitis [1–3]. C. difficile infection (CDI) is a major medical problem in many health care facilities, including hospitals, long-term care facilities, and nursing homes [4–6]. Accurate and timely diagnosis is necessary both for appropriate clinical management of the patients and for the timely implementation of infection control [7,8].

Traditionally, a cell culture cytotoxicity assay has been widely used for CDI diagnosis due to its high sensitivity, together with toxigenic culture [9,10]. An enzyme immunoassay (EIA) for toxins A/B and glutamate dehydrogenase (GDH) has also been one of the widely used test methods until recently, although it has a low sensitivity and specificity compared to toxigenic culture [11,12]. In recent years, several nucleic acid amplification tests (NAATs) based on real-time PCR or loop-mediated isothermal amplification (LAMP) have been developed for the diagnosis of CDI, which directly detect the tcdA and tcdB genes from stool specimens with high sensitivity (>90%) and specificity (>99%) [13,14]. Many laboratories...
use stand-alone tests or diagnostic algorithms to aid in the diagnosis of CDI [15]. While each of these test methods or diagnostic algorithms have their own benefits, the most critical factor to the accurate diagnosis of C. difficile is the quality of the fecal samples (and the corresponding targets of the test methods, e.g., cell viability, cytotoxicity, DNA stability, etc.). Ideally, it is best to do diagnostic assays immediately after sampling of specimens. Unless properly handled, the quality of a stool sample decreases from the time of collection until testing. Appropriate storage of fecal samples is essential to avoid the introduction of post-collection bias in test result. Several studies have investigated the impact of different storage conditions on the quality of stool samples [16–23]; however, these previous studies have some limitations that minimize their utility and there were experimental gaps in the storage conditions tested in the studies, preventing pragmatic storage strategies from being generated for stand-alone tests or currently accepted CDI diagnosis algorithms.

The aim of this study was to provide a practical handling and storage strategy for fecal samples with regards to the test methods used to aid in the diagnosis of CDI. We conducted a comprehensive review of the published articles (i.e., bibliomic data) in order to systematically organize the storage conditions and of the CDI test methods and results in order to find data gaps. We examined the differences in the numbers of C. difficile vegetative and spore cells during storage at −70 °C, −20 °C, 4 °C, and RT over 28 days, which are typical storage temperature conditions. We also examined the stability of C. difficile DNA in the fecal sample over the course of sample storage, using a qPCR method that detects C. difficile toxin A and B genes. Comparative integration of previous and current results allowed us to update and recommend more pragmatic protocols for fecal handling and storage processes.

2. Results

Figure 1 shows the procedures used for the development of strategy adopted in this study: step 1, analyze bibliomic data; step 2, perform an experiment to fix the shortfall; step 3, compare and summarize the storage effects; step 4, develop a strategy; step 5, verify the strategy via internal review.

2.1. Step 1: Analyze Bibliomic Data

Out of 13,100 peer reviewed articles retrieved from a primary search using “C. difficile [title]”, 8 publications were identified to provide experimental information on the storage
effects on the targets of *C. difficile* detection methods. These 8 articles, which had an average number of 36 citations per paper, provided a total of 16 detection method categories (Table 1). Among these, cells, spores, and proteins were used as the targets of *C. difficile* detection in 7 and 6 articles, respectively, while only one article used DNA for the target of *C. difficile* detection (Table 1). The test method, i.e., toxigenic culture, was used in 7 articles, which had 372 citations.

Table 1. Total numbers of articles on fecal storage conditions published in journals indexed by Google Scholar.

| Article Classified in | Target | Test Method 1 | Number of Articles | Citations | Citations Per Article |
|-----------------------|--------|---------------|--------------------|-----------|-----------------------|
| Cell/spore            | Viability | TC            | 7                  | 280       | 40.0                  |
|                       | Cell count | TC            | 1                  | 92        | 92.0                  |
| Protein               | TcdA/B | CCCNA | 3                  | 260       | 86.7                  |
|                       | GDH   | EIA           | 2                  | 67        | 33.5                  |
|                       | GDH assay | NAAT | 2                  | 5         | 2.5                   |
| DNA                   | tcdA/B | NAAT | 1                  | 3         | 3.0                   |
| Sum                   |        |               | 707                |           |                       |

1 Abbreviations: TC, toxigenic culture; CCCNA, cell culture cytotoxicity neutralization assay; GDH, glutamate dehydrogenase; EIA, enzyme immunoassay; NAAT, nucleic acid amplification tests.

2.2. Step 2: Perform an Experiment to Bridge the Gaps

2.2.1. Vegetative Cell and Spore Counts of *C. difficile* at Different Storage Conditions

The numbers of viable *C. difficile* cells were measured for all storage conditions. Fecal samples were initially spiked with 8 log CFU of *C. difficile* ATCC BAA-2155 per mL. As shown in Figure 2a, the results of plate counting on day 1 showed that the numbers of vegetative cells markedly decreased by 56.3% and 53.8% compared with the initial cell numbers at temperatures of −70 °C and −20 °C, respectively. At day 2, there were additional decreases in the numbers of viable cells (47.5% and 46.3% of day 0 counts, respectively) at these temperatures. The survival of *C. difficile* vegetative cells stored at 4 °C and RT, on the other hand, showed less of a decrease at day 1 (80% of day 0 counts), in contrast to the counts observed under freezing temperatures. From day 1 until day 28, the numbers of viable cells remained quite constant at 3 storage temperatures −70 °C, −20 °C, and 4 °C, with the exception of the viability from day 2 to day 5 at 4 °C, which was slightly higher than the viability at −70 °C and −20 °C. Over the entire 28 days, among the 4 storage temperatures, the biggest decrease in the viability of vegetative cells was observed at RT. These counts decreased to 45% and to 36.3% at day 2 and day 28, respectively.

Plate counting of the fecal samples treated with alcohol detected gradual decreases in the numbers of *C. difficile* spores for all storage conditions (Figure 2a). The extent of the decreases in the numbers of spores for storage temperatures overall showed similar patterns over 28 days for the vegetative cells. The results of the culture showed that the numbers of spores at storage temperatures of −70 °C, −20 °C, and 4 °C decreased to around 75% at day 1 and around 65% at day 28; however, storage of the below freezing temperatures (−70 °C and −20 °C) appeared to produce slightly higher numbers of spores overall than at 4 °C. The lowest numbers of spores were detected at RT, particularly after day 7.
2.2.2. C. difficile DNA Stability at Different Storage Conditions

The results of the tcdA qPCR assay (Figure 2b) showed that when the total C. difficile concentrations were estimated from Cq values, the overall concentrations were similar, at 7.8 to 8.6 log CFU per mL, for all time points, except that there were slight decreases in concentrations at 4 °C and RT that dropped to as low as 7.0 to 7.6 log CFU per mL after day 7. The qPCR assay for tcdB (Figure 2b) also showed that overall, a similar number of C. difficile cells ranged between 8.1 to 8.6 log CFU per mL for all temperatures over time, except a lower number of cells (1.2 log CFU per mL) calculated at RT after day 28, compared with day 0.

2.3. Step 3: Compare the Storage Effects

A total of 9 studies (8 previous studies and this study) were systematically integrated to compare the storage effects on the quality of fecal specimens with C. difficile detection (Table 2).

2.4. Step 4: Develop Handling and Storage Strategy

Figure 3 shows the strategy developed for stool sample handling and storage and the corresponding test methods.

The general strategy for fecal sample storage for CDI diagnosis methods is as follows:

- Shorten the handling time;
- Avoid repeated dramatic temperature fluctuation;
- Avoid freeze–thaw cycles;
- Before testing the samples, distribute the feces into aliquots for future application;
- Store the aliquots at room, refrigeration (4 °C), and freezing (−20 °C or −70 °C) temperatures (if possible).

Specific strategies for fecal sample storage for CDI diagnosis methods are as follows:

- At day 0, use stool samples stored at RT or refrigeration temperature (4 °C) for all test methods (TC, GDH, EIA, CCCNA, and NAAT);
- For TC before day 2, use stool samples stored at RT or 4 °C;
- For TC after day 2, use stool samples stored at 4 °C or a freeze temperature of −20 °C or −70 °C;
- For short-term (72 h) GDH assays, use stool samples stored at RT, 4 °C, or −20 °C;
- For long-term (after 72 h) GDH assays, use stool samples stored at 4 °C or −20 °C;
For EIA during either short-term or long-term storage, use stool samples stored at 4 °C or a freeze temperature of −20 °C or −70 °C;
For CCCNA during short-term storage, use stool samples stored at RT and 4 °C;
For CCCNA during long-term storage, use stool samples stored at 4 °C;
For NAAT, use any stool sample stored at any temperature (RT, 4 °C, −20 °C, or −70 °C).

Figure 3. A schematic overview of the practical strategy used for stool specimen handling, storage conditions (temperatures and periods), and the corresponding detection methods for C. difficile diagnosis. Circles in yellow represent the relative effectiveness of the strategy based on all experimental information compared in this study. The use of three circles indicates strongly recommended, as rated when the results of C. difficile diagnosis were stable under given storage temperature, period, and test methods.
Table 2. Summary of previous and current studies investigating storage effects on the stool specimens with C. difficile.

| Experiment            | Storage condition | Toxigenic culture | Viability | Cell counts | Protein-based |
|-----------------------|-------------------|-------------------|-----------|-------------|---------------|
|                       |                   |                   |           |             |               |
|                       |                   |                   |           | N/A         |               |
|                       |                   |                   |           | N/A         |               |
|                       |                   |                   |           | N/A         |               |
| Bowden and Riley (1986) [19] | 10 0/5/25 Aerobic | Recovered during 10 d at 5 °C | Stay stable (no storage impact) | N/A |               |
| Weese et al. (2000) [23] | 30–60 56 Aerobic | Recovered during 56 d at −20 °C/4 °C | N/A | N/A | N/A |
| Freeman and Wilcox (2003) [20] | 4/25 Aerobic | Recovered during 56 d at 4 °C/25 °C | N/A | N/A | N/A |
| Arroyo et al. (2005) [17] | 3 4/RT Aerobic | Recovered after 72 h at 4 °C/RT | N/A | N/A | N/A |
| Alfa et al. (2014) [16] | 10 28 Aerobic | Recovered during 28 d at 4 °C/20 °C | N/A | N/A | N/A |
| Becker et al. (2015) [18] | 60 −20 Aerobic | Recovered during at least 60 d at −20 °C or colder (100% agreement between fresh and storage samples) | N/A | N/A | N/A |
| Peterson et al. (2017) [21] | 0/−30/4/10 Aerobic | Recovered during 28 d at −70 °C/−20 °C/4 °C/RT | N/A | N/A | N/A |
| Schora et al. (2018) [22] | 120 −70/−20/4/RT Aerobic | Decreased until 3 d at −70 °C/−20 °C/4 °C/RT and then stay stable until 28 d | N/A | N/A | N/A |
| This Study            | 120 28 −80/−30/4/10 Aerobic | Recovered during at least 60 d at −20 °C or colder (100% agreement between fresh and storage samples) | N/A | N/A | N/A |
|                       |                   |                   |           |             |               |

Pathogens 2021, 10, 1049

6 of 13
Table 2. Cont.

| Experiment                  | Bowman and Riley (1986) [19] | Weese et al. (2000) [23] | Freeman and Wilcox (2003) [20] | Arroyo et al. (2005) [17] | Alfa et al. (2014) [16] | Becker et al. (2015) [18] | Peterson et al. (2017) [21] | Schora et al. (2018) [22] | This Study |
|-----------------------------|-----------------------------|--------------------------|-------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|-----------|
| DNA-based                   | N/A                         | N/A                      | N/A                           | N/A                      | N/A                      | N/A                      | N/A                      | N/A                      | N/A       |
| Antigen assay (GDH)         | N/A                         | N/A                      | N/A                           | N/A                      | GDH remained detectable 100% up to 72 h at 4 °C/RT | GDH remained detectable during 28 d at 4 °C/20 °C | N/A                      | N/A                      | N/A       |
| NAAT                        | N/A                         | N/A                      | N/A                           | N/A                      | N/A                      | N/A                      | N/A                      | 97.6% agreement between fresh and frozen storage samples | N/A       |
| A qPCR-based cell count     | 100%                        | 100%                     | 100%                          | 100%                     | 97.6%                    | 97.6%                    | 97.6%                    | 97.6%                    | 97.6%     |

N/A, not available.
2.5. Step 5: Verify the Strategy by Internal Review

Drs. Huizhong Chen and Kidon Sung (within the agency) internally reviewed the strategy.

3. Discussion

Collecting and storing fecal specimens for testing is a routine but critical process to ensure accurate results in the clinical laboratory. Stool specimens for CDI diagnosis should be transported to the laboratory as soon as possible. If testing cannot be performed immediately, it is currently recommended that stool specimens be stored at 2 °C to 8 °C for up to 24 hours (or at 4 °C prior to testing) or frozen at −70 °C for longer storage [24]. When toxin testing has been completed, the fecal sample should be frozen at −20 °C for up to 3 months in order to allow culture at a later time for typing if required [25]. The current recommendations cover some of the key steps in handling stool samples; however, neither of these recommendations provides any information on the impacts of more prolonged stool storage at different temperatures on the stability of the test targets.

As shown in the integrated data (Table 2), sample storage at different conditions apparently influences the stability of the targets (i.e., bacterium or spore, glutamate dehydrogenase, toxins, and toxin genes) of C. difficile test methods with different degrees of influence. It is evident that improperly stored samples can compromise the function of diagnostic methods and can produce misleading results. In this respect, the strategy used in this study, which established a reasonable link between stool storage and the corresponding CDI test methods, can reduce false-negative diagnosis.

Currently, storing fecal specimens at refrigeration temperatures (2–8 °C) is a common practice for short-term storage (up to 24 h or prior to testing) [24]. Interestingly, as revealed in this study, storage at refrigeration temperature (4 °C) of stool specimens used for CDI diagnosis is recommended not only for short-term storage (within 3 days), but also for long-term (~60 days) storage for all the test methods, including TC. Although the numbers of vegetative and spore cells during storage at all temperatures decreased (decreased until 3 days and then stabilized, as shown in Figure 2A until 28 days), previous studies reported that patient stools stored at 4 °C showed consistent binary test results from TC tests over at least 56 days [17,20]. Freeman et al. confirmed that single and multiple exposures of samples to 4 °C had little effect upon the C. difficile toxin titer and recommended that specimens should be stored at 4 °C instead of −20 °C to minimize toxin degradation [20]. Using either CDI patient stool samples or contrived fecal samples spiked with C. difficile stored at 4 °C, previous studies showed that enzyme immunoassay tests for toxins A/B and GDH also gave very stable test results at 28–120 days (>90% reproducibility) [22]. For molecular assays, as shown in our results, stool samples stored at 4 °C were stable for NAAT for at least 28 days. Storing fecal samples at 4 °C, which is more reliable than subzero storage systems, also provides collateral benefits, such as avoiding repetitive freeze–thaw cycles and reducing storage costs.

Laboratory diagnosis is a crucial part of the management of patients with suspected CDI. A plethora of testing methods have spawned diverse approaches to CDI diagnosis, including 2-step and 3-step testing algorithms and the use of stand-alone tests. Together with the evolution of test methods, C. difficile guidelines are also evolving to recommend updated treatments and protocols. Considering that quality of fecal samples is the key to successful diagnosis of CDI, C. difficile guidelines should include pragmatic advice on the impacts that stool quality have on the diagnostic approaches used over various storage conditions. A reasonable review process, involving systematic review of the bibliomic data and gap-filling with additional experimental data, is essential to enhance the quality of the recommendations with the aim of updating guidelines. The strategy developed in this study should be continuously updated with new basic and clinical data to ensure the validity of the strategy.
4. Materials and Methods

4.1. Literature Search

To identify potentially relevant articles, we searched Google Scholar (https://scholar.google.com/), PubMed (https://www.ncbi.nlm.nih.gov/pubmed/), and Web of Science (https://apps.webofknowledge.com/WOS_GeneralSearch_input.do?product=WOS&search_mode=GeneralSearch&SID=5A2X9WMkPLLdOFcJtRE&preferencesSaved=) using the following search terms: “C. difficile” in title, “C. difficile” in title, AND “storage” in any fields.

4.2. Bacterial Culture

Twenty-one C. difficile reference strains (Table A1) were purchased from American Type Culture Collection (ATCC). Cells of C. difficile strains were cultured onto cycloserine-cefoxitin-fructose agar (CCFA, OXOID, Cheshire, UK) plates, supplemented with 5% defibrinated horse blood (OXOID), then incubated at 37 °C for 48 h in an AS-580 anaerobic chamber (Anaerobe System, CA, USA). The growth of C. difficile was identified on the basis of typical odor and colony morphology. For the storage condition experiments, bacteria anaerobically grown on brain–heart infusion (BHI) agar plates at 37 °C for 48 h were transferred into BHI broth supplemented with 0.5% yeast extract and 0.1% cysteine, then incubated at 37 °C overnight. Cultures were harvested by centrifugation at 13,000 g for 10 min, then subsequently the supernatant was removed.

4.3. Spiked Fecal and Storage Conditions

The use of human fecal samples was approved by the FDA Research Involving Human Subjects Committee (RIHSC #16-032T). Fecal samples were obtained from 3 healthy adult individuals and autoclaved to eliminate potential viable C. difficile cells and spores to ensure accurate counts of C. difficile in subsequent experiments. Autoclaved fecal samples were diluted to 3% (w/v) with pre-reduced phosphate-buffered saline (PBS, composed of 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2.0 mM KH2PO4, pH 7.4) and spiked with the same volume of BHI broth-cultured C. difficile ATCC BAA-2155 (2 × 10⁸ CFU/mL). Spiked fecal samples were divided into 120 aliquots of 1 mL in Eppendorf tubes and sealed tightly with parafilm, then 30 aliquots each were placed at −70 °C, −20 °C, 4 °C, and room temperature. On days 0, 1, 2, 5, 7, 14, and 28, two 1 mL aliquots were taken from each storage condition and assayed for either vegetative and spore cell counts (Figure 2a) or real-time PCR testing (Figure 2b).

4.4. Vegetative and Spore Cell Counts from Plates

For initial vegetative cell counts, 100 µL aliquots of the spiked fecal samples taken from all storage conditions were thoroughly mixed with 900 µL of sterilized PBS. The aliquots were then 10-fold serially diluted with PBS and 100 µL of each dilution was spread onto BHI agar plates. Following incubation at 37 °C under anaerobic conditions for 72 h, the numbers of colonies were enumerated [26,27].

For the counts of spore cells, 200 µL of each spiked fecal sample was mixed with an equal volume of ethanol and incubated at RT for 1 h. The mixtures were then 10-fold serially diluted with PBS and 100 µL of each dilution was spread onto CCFA supplemented with 5% defibrinated horse blood, which was anaerobically incubated and counted as described above [26,27].

4.5. Real-Time PCR Detection Assay

Primer 3 (http://bioinfo.ut.ee/primer3-0.4.0/) was used to design tcdA (internal fragment of the toxin A gene, CDIF630_00776) and tcdB (internal fragment of the toxin B, CDIF630_00773) primers (Table 3). The primer sequences were evaluated by using the Basic Local Alignment Search Tool (BLAST) with specificity of primers. Using all 21 strains (Table A1), we tested the new primers, together with reference primers (Table 3) [28]. The estimated sensitivity of the new qPCR primers (Table A2) was 100% using 21 C. difficile strains (Table A1). The new primers detected the two toxin genes at lower cycle quantifica-
tion (Cq) values than a set of previously published reference primers (Table A2). The limits of detection (LoD) of the new primers for \( tcdA \) and \( tcdB \) genes were \( 3.51 \times 10^3 \) CFU per mL and \( 1.00 \times 10^2 \) CFU per mL, corresponding to 35.65 and 34.50 of Cq value, respectively [29].

Table 3. Real-time PCR primers and probes specific for toxin A (\( tcdA \)) and B (\( tcdB \)) genes for the detection of \( C. \) difficile.

| Primer     | Sequence                    | Target |
|------------|-----------------------------|--------|
| \( tcdA-7582F \) | CCTGATGGATTTGAATACCTTTGC   | \( tcdA \) |
| \( tcdA-7784R \) | CCATTCGCACCCATAGCTGTA       | \( tcdA \) |
| \( tcdB-3005F \) | CAGATGCAGGCAAAGTTGTTGA      | \( tcdB \) |
| \( tcdB-3161R \) | GGGTCACTCGTTTCACTTAGC       | \( tcdB \) |

Reference primers used by Kilic et al (2015) [28]

| F          | TGATAACGTATAGCTTGACC        | \( tcdA \) |
| R          | ATGGTTTACCTCAGATAGG         | \( tcdA \) |
| F          | GAAGGATTACCTGTAATTCGC       | \( tcdB \) |
| R          | CTGCCATTATACTATCTTAGC       | \( tcdB \) |

Total genomic DNA samples were extracted using DNA isolation QIAamp PowerFecal DNA Kit (Qiagen, Hilden, Germany). Concentrations of the extracted DNA samples and their purity were measured using a NanoDrop instrument (Thermo Fisher Scientific, USA). To quantify the total numbers of bacteria, standard curves were generated by plotting Cq values versus the concentrations of purified PCR products obtained via amplification of the genes from the genomic DNA of \( C. \) difficile ATCC BAA-2155. The real-time PCR reaction (15 \( \mu \)L) contained 1.5 \( \mu \)L of template DNA and 10 \( \mu \)M of each primer, 3 \( \mu \)L nuclease-free water, and 7.5 \( \mu \)L of Faststart Universal SYBR Green Master (Roche, Basel, Switzerland). Real-time PCR amplification reactions were performed with the CFX96 (Bio-Rad, USA) and the following conditions were used: 1 cycle of 94 °C for 3 min; followed by 40 cycles of 94 °C for 30 sec, 60 °C for 30 sec, and 72 °C for 30 sec; 72 °C for 5 min.

4.6. Patient and Public Involvement

No patients were involved in the development of the research question, design, or implementation of the study, or interpretation of the results.

**Author Contributions:** Conceptualization, S.-J.K., S.L.F., R.N., O.K., and C.E.C.; methodology and data analysis, S.W.N., M.K., S.-J.K., and O.K.; writing—original draft preparation, S.W.N., M.K., S.-J.K., S.L.F., R.N., O.K., and C.E.C.; funding acquisition, C.E.C. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported in part by an appointment to the Postgraduate Research Fellowship Program at the National Center for Toxicological Research, administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the U.S. Food and Drug Administration.

**Institutional Review Board Statement:** The use of human fecal samples was approved by the FDA Research Involving Human Subjects Committee (RIHSC #16-032T).

**Informed Consent Statement:** Any research article describing a study involving humans should contain this statement.

**Data Availability Statement:** https://www.mdpi.com/ethics.

**Acknowledgments:** We thank Gerald Noel, Shawar Ribhi, Huizhong Chen, and Kidon Sung for critical review of the manuscript. The opinions and views presented in this article do not necessarily reflect current or future opinions or policies of the U.S. FDA.

**Conflicts of Interest:** The authors declare no conflict of interest.
Appendix A

Table A1. Toxigenic strains of *C. difficile* used for analytical sensitivity studies.

| ATCC Strain | Strain   | Toxinotype | Toxin | A | B | CDT |
|-------------|----------|------------|-------|---|---|-----|
| 43598       | 1470     | VIII       | −     | + |   | +   |
| 17857       | 870      | O          | +     | + |   | −   |
| 17858       | 1253     | O          | +     | + |   | −   |
| 43255       | VPI 10463| O          | +     | + |   | −   |
| 43594       | W1194    | O          | +     | + |   | −   |
| 43596       | 545      | O          | +     | + |   | −   |
| 43599       | 2022     | O          | +     | + |   | −   |
| 43600       | 2149     | O          | +     | + |   | −   |
| 51695       | BDMS 18 AN| O     | +     | + |   | −   |
| 700792      | 14797-2  | O          | +     | + |   | −   |
| 9689        | 90556-M6S| O          | +     | + |   | −   |
| BAA-1382    | 630      | O          | +     | + |   | −   |
| BAA-1805    | N/A      | IIIb       | +     | + |   | +   |
| BAA-1870    | 4118     | IIIb       | +     | + |   | +   |
| BAA-1871    | 4111     | O          | +     | + |   | −   |
| BAA-1872    | 4206     | O          | +     | + |   | −   |
| BAA1873     | 5283     | O          | +     | + |   | −   |
| BAA-1874    | 4205     | O          | +     | + |   | −   |
| BAA-1875    | 5325     | V          | +     | + |   | −   |
| BAA-2155    | LBM 0801058| XXII | +     | + |   | +   |
| BAA-2156    | LBM 0801040| O     | +     | + |   | −   |

Appendix B

Table A2. Real-time PCR assay used to determine sensitivity using the reference primers and the primers designed in this study based on cycle quantification (Cq).

| Name       | Toxin A (tcdA) | Toxin B (tcdB) |
|------------|----------------|----------------|
|            | Ref. 1 | This Study | Difference  | Ref. 2 | This Study | Difference  |
| ATCC 43598 | N/S 3   | N/S 3      | − N/S 3     | 24.92  | 16.58      | 8.34        |
| ATCC 17857 | 21.75   | 18.48      | 3.27        | 26.07  | 16.07      | 10.00       |
| ATCC 17858 | 21.08   | 22.42      | −1.34       | 24.73  | 17.12      | 7.61        |
| ATCC 43255 | 21.76   | 18.59      | 3.16        | 26.02  | 16.08      | 9.94        |
| ATCC 43594 | 21.03   | 19.12      | 1.91        | 25.04  | 18.31      | 6.73        |
| ATCC 43596 | 23.15   | 20.52      | 2.63        | 26.92  | 14.72      | 12.20       |
| ATCC 43599 | 21.47   | 19.40      | 2.07        | 25.32  | 15.06      | 10.25       |
| ATCC 43600 | 23.97   | 19.46      | 4.50        | 28.75  | 14.54      | 14.20       |
| ATCC 51695 | 20.59   | 20.45      | 0.14        | 24.19  | 16.57      | 7.62        |
| ATCC 700792| 21.36   | 19.32      | 2.03        | 25.72  | 16.58      | 9.14        |
| ATCC 9689  | 19.79   | 20.14      | −0.35       | 24.15  | 18.94      | 5.21        |
| ATCC BAA-1382| 20.25 | 22.63      | −2.38       | 24.40  | 18.74      | 5.65        |
| ATCC BAA-1805| 23.67 | 18.80      | 4.87        | 22.22  | 22.99      | −0.77       |
| ATCC BAA-1870| 24.44 | 20.47      | 3.97        | 28.93  | 17.44      | 11.50       |
| ATCC BAA-1871| 21.03 | 22.08      | −1.06       | 25.17  | 16.64      | 8.53        |
| ATCC BAA-1872| 20.65 | 21.17      | −0.52       | 24.21  | 15.77      | 8.43        |
| ATCC BAA-1873| 20.78 | 17.11      | 3.68        | 19.76  | 18.24      | 1.52        |
| ATCC BAA-1874| 22.22 | 21.00      | 1.22        | 26.11  | 16.52      | 9.59        |
| ATCC BAA-1875| 20.20 | 20.38      | −0.18       | 18.68  | 26.25      | −7.56       |
| ATCC BAA-2155| 21.11 | 20.42      | 0.68        | 25.34  | 15.55      | 9.79        |
| ATCC BAA-2156| 21.18 | 18.26      | 2.92        | 24.93  | 15.80      | 9.13        |

Average 21.58 20.01 1.56 24.83 17.40 7.44

1 Ref., F and R for tcdA; this study, tcdA-7582F and tcdA-7784R (please refer to Table 3). 2 Ref., F and R for tcdB; this study, tcdB-3005F and tcdB-3161R (please refer to Table 3). 3 N/S, non-specific.
27. Surawicz, C.M.; Brandt, L.J.; Binion, D.G.; Ananthakrishnan, A.N.; Curry, S.R.; Gilligan, P.H.; McFarland, L.V.; Mellow, M.; Zuckerbraun, B.S. Guidelines for diagnosis, treatment, and prevention of *Clostridium difficile* infections. *Am. J. Gastroenterol.* 2013, 108, 478–498. [CrossRef] [PubMed]

28. Kilic, A.; Alam, M.J.; Tisdel, N.L.; Shah, D.N.; Ypar, M.; Lasco, T.M.; Garey, K.W. Multiplex Real-Time PCR Method for Simultaneous Identification and Toxigenic Type Characterization of *Clostridium difficile* From Stool Samples. *Ann. Lab. Med.* 2015, 35, 306–313. [CrossRef] [PubMed]

29. Armbruster, D.A.; Fry, T. Limit of blank, limit of detection and limit of quantitation. *Clin. Biochem. Rev.* 2008, 29 (Suppl. 1), S49–S52.